Fuso Pharmaceutical Industries,Ltd. Logo

Fuso Pharmaceutical Industries,Ltd.

Develops and manufactures pharmaceuticals, focusing on infusions and dialysis solutions.

4538 | T

Overview

Corporate Details

ISIN(s):
JP3823600006
LEI:
Country:
Japan
Address:
大阪市中央区道修町一丁目7番10号

Description

Fuso Pharmaceutical Industries, Ltd. is a company engaged in the development, manufacture, and sale of pharmaceuticals and medical equipment. The company's core business centers on providing essential medical products, with a primary focus on infusions, such as transfusion fluids, and solutions for artificial kidney dialysis. Its portfolio also includes a wide range of injectables for various therapeutic applications. In addition to supplying prescription drugs to medical institutions, Fuso Pharmaceutical Industries also develops and markets over-the-counter (OTC) medications. The company maintains a commitment to research and development, actively managing a drug pipeline and conducting clinical trials to introduce new treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-11-10 01:44
確認書
Japanese 9.6 KB
2022-11-10 01:42
四半期報告書-第100期第2四半期(令和4年7月1日-令和4年9月30日)
Japanese 185.3 KB
2022-08-09 07:03
確認書
Japanese 9.6 KB
2022-08-09 07:00
四半期報告書-第100期第1四半期(令和4年4月1日-令和4年6月30日)
Japanese 147.2 KB
2022-06-29 07:55
内部統制報告書-第99期(令和3年4月1日-令和4年3月31日)
Japanese 24.4 KB
2022-06-29 07:52
確認書
Japanese 9.5 KB
2022-06-29 07:48
有価証券報告書-第99期(令和3年4月1日-令和4年3月31日)
Japanese 787.8 KB
2022-02-10 01:21
四半期報告書-第99期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 163.6 KB
2021-11-12 01:12
四半期報告書-第99期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 196.2 KB
2021-08-11 06:51
四半期報告書-第99期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 162.2 KB
2021-06-29 06:10
内部統制報告書-第98期(令和2年4月1日-令和3年3月31日)
Japanese 24.4 KB
2021-06-29 06:09
確認書
Japanese 9.5 KB
2021-06-29 06:08
有価証券報告書-第98期(令和2年4月1日-令和3年3月31日)
Japanese 782.9 KB
2021-02-10 01:29
四半期報告書-第98期第3四半期(令和2年10月1日-令和2年12月31日)
Japanese 153.5 KB
2020-11-11 01:17
四半期報告書-第98期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese 185.1 KB

Automate Your Workflow. Get a real-time feed of all Fuso Pharmaceutical Industries,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fuso Pharmaceutical Industries,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fuso Pharmaceutical Industries,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.